<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672100</url>
  </required_header>
  <id_info>
    <org_study_id>HIC 2007-198</org_study_id>
    <nct_id>NCT00672100</nct_id>
  </id_info>
  <brief_title>Initial Local Anesthetic Dose With Continuous Interscalene Analgesia</brief_title>
  <official_title>The Effect Of Initial Local Anesthetic Dose With Continuous Interscalene Analgesia On Postoperative Pain And Diaphragmatic Function In Arthroscopic Shoulder Surgery Patients: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beaumont Foundation of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine a minimally effective initial local anesthetic bolus required to
      provide satisfactory analgesia using continuous brachial plexus infusion following
      arthroscopic shoulder surgery using a double-blind, randomized, study comparing 3 initial
      doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims:

        1. To compare pain ratings and supplemental analgesic requirements at discharge from PACU,
           24 hours, and 48 hours and 12 weeks following 5, 10, and 20 ml boluses.

        2. To compare adverse events including clinical dysphonia, Horner's syndrome, dyspnea,
           unexpected hospitalization, evidence of local anesthetic toxicity, and hand weakness at
           discharge from PACU following 5, 10, and 20 ml boluses.

        3. To compare impairment in diaphragmatic excursion at discharge from PACU following 5, 10,
           and 20 ml boluses.

        4. To compare patients' satisfaction with analgesia at 24 and 48 hours following 5, 10, and
           20 ml boluses.

        5. To compare patient rating of functional outcome at baseline and at 12 weeks following 5,
           10, and 20 ml boluses.

        6. To compare the rate of general anesthesia required following 5, 10, and 20 ml boluses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Measurements Via Numeric Pain Rating Scales (NRS)</measure>
    <time_frame>Discharge, 24 h, 48h, 12 weeks</time_frame>
    <description>Pain was reported via NRS ranging from 0 (no pain) to 10 (worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diaphragmatic Displacement From Baseline to Post-surgery</measure>
    <time_frame>Baseline, Post anesthesia care unit (PACU) - within 8 hours</time_frame>
    <description>Diaphragm displacement from exhale to inhale. The baseline diaphragm measurement was obtained pre-operatively before the block was administered prior to surgery. This was again measured post-operatively before the patient's discharge from the Post-anesthesia Care Unit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Considered the Analgesic Technique &quot;Helpful&quot; or &quot;Extremely Helpful&quot;</measure>
    <time_frame>at 24 and 48 hours after discharge from the hospital</time_frame>
    <description>Participants were asked to rate the helpfulness of their infusion:
extremely harmful
harmful
neutral
not harmful, but not helpful
helpful
extremely helpful</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome - Simple Shoulder Test (SST)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>At baseline and again at 12 weeks subjects completed the Simple Shoulder Test. This test is a series of 12 (yes/no) questions. Participants get 1 point if they answer yes (they can perform the task) and 0 if they answer no. Total possible range is from 0-12. This has been shown to be a valid, reliable and consistent for subjects up to and including 60 years of age when similar injuries (rotator cuff dysfunction) are assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial Bolus 5 ml Ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial Bolus 10 ml Ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial Bolus 20 ml Ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Initial Bolus 5 ml Ropivacaine via interscalene injection</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Initial Bolus 10 ml Ropivacaine via interscalene injection</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Initial Bolus 20 ml Ropivacaine via interscalene injection</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent prior to participation in the study.

          -  Is scheduled to undergo Arthroscopic Rotator Cuff Repair, defined as arthroscopically
             assisted repair of any of the muscles or tendons comprising the rotator cuff.

          -  If subject is a female of childbearing potential, have a negative pregnancy test on
             the day of surgery per standard of care

          -  Be at least 18, but not more than 80 years of age

          -  Have an ASA risk class of I, II, or III according to the American Society of
             Anesthesiologists (ASA).

          -  Have the ability to read and understand the study procedures and the use of the pain
             scales. Must have the ability to communicate meaningfully with the Study Investigator
             and staff.

          -  Be free of other physical, mental, or medical conditions, which in the opinion of the
             Investigator, makes study participation inadvisable.

        Exclusion Criteria:

          -  Subjects requiring daily opioids equivalent to greater than 40 mg oxycodone for over 2
             weeks prior to the study.

          -  Has significant preexisting pulmonary (respiratory/breathing) disease, diaphragmatic
             paralysis or history of phrenic nerve injury (problems with the diaphragm causing
             breathing difficulties).

          -  Has significant medical disease(s), laboratory abnormalities or condition(s) that in
             the Investigator's judgment could compromise the subject's welfare, ability to
             communicate with the study staff, complete study activities, or would otherwise
             contraindicate study participation.

          -  Has known significant hypersensitivity to opioids, Ropivacaine, or the inactive
             ingredients (excipients) of the study medications.

          -  Has known or suspected history of alcohol or drug abuse or dependence within the
             previous 2 years.

          -  Has clinically significant liver disease, or other condition (e.g., alcoholism,
             cirrhosis, or hepatitis) based on medical history and examination.

          -  Has participated in another clinical Study (investigational or marketed product within
             30 days of surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Hartrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospitals</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hartrick CT, Tang YS, Siwek D, Murray R, Hunstad D, Smith G. The effect of initial local anesthetic dose with continuous interscalene analgesia on postoperative pain and diaphragmatic function in patients undergoing arthroscopic shoulder surgery: a double-blind, randomized controlled trial. BMC Anesthesiol. 2012 Mar 23;12:6. doi: 10.1186/1471-2253-12-6.</citation>
    <PMID>22443231</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>July 12, 2011</results_first_submitted>
  <results_first_submitted_qc>May 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2013</results_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Nerve Infusion,</keyword>
  <keyword>continuous brachial plexus block,</keyword>
  <keyword>post-operative pain</keyword>
  <keyword>diaphragmatic paresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were identified from the surgical schedule. Subjects consented using the most current IRB-approved consent form. Informed consent were administered in the pre-operative suites prior to receiving any treatment.
Recruitment started after approval was obtained from the IRB. Recruitment period was Jan 2009 to Dec 2009.</recruitment_details>
      <pre_assignment_details>Subjects were screened per protocol, those that met all inclusion criteria and did not meet any exclusion criteria were randomized per protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine 5 mL</title>
          <description>Initial Bolus 0f 5 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="P2">
          <title>Ropivacaine 10 mL</title>
          <description>Initial Bolus 0f 10 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="P3">
          <title>Ropivacaine 20 mL</title>
          <description>Initial Bolus 0f 20 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PACU (Within 8 Hours)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine 5 mL</title>
          <description>Initial Bolus 0f 5 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="B2">
          <title>Ropivacaine 10 mL</title>
          <description>Initial Bolus 0f 10 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="B3">
          <title>Ropivacaine 20 mL</title>
          <description>Initial Bolus 0f 20 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Measurements Via Numeric Pain Rating Scales (NRS)</title>
        <description>Pain was reported via NRS ranging from 0 (no pain) to 10 (worst pain imaginable)</description>
        <time_frame>Discharge, 24 h, 48h, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 5 mL</title>
            <description>Initial Bolus 0f 5 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 10 mL</title>
            <description>Initial Bolus 0f 10 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 20 mL</title>
            <description>Initial Bolus 0f 20 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Measurements Via Numeric Pain Rating Scales (NRS)</title>
          <description>Pain was reported via NRS ranging from 0 (no pain) to 10 (worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NRS at Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="0.61" upper_limit="4.71"/>
                    <measurement group_id="O2" value="1.58" lower_limit="-0.18" upper_limit="3.35"/>
                    <measurement group_id="O3" value="0.62" lower_limit="-0.26" upper_limit="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS at 24 hours post discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" lower_limit="2.03" upper_limit="5.30"/>
                    <measurement group_id="O2" value="3.33" lower_limit="1.57" upper_limit="5.10"/>
                    <measurement group_id="O3" value="2.54" lower_limit="1.09" upper_limit="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS at 48 hours post discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="1.08" upper_limit="4.25"/>
                    <measurement group_id="O2" value="2.08" lower_limit="0.66" upper_limit="3.50"/>
                    <measurement group_id="O3" value="2.15" lower_limit="0.92" upper_limit="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NRS at 12 weeks post discharge (n=11, 12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.50" upper_limit="2.50"/>
                    <measurement group_id="O2" value="2.42" lower_limit="0.55" upper_limit="4.28"/>
                    <measurement group_id="O3" value="1.15" lower_limit="0.42" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Diaphragmatic Displacement From Baseline to Post-surgery</title>
        <description>Diaphragm displacement from exhale to inhale. The baseline diaphragm measurement was obtained pre-operatively before the block was administered prior to surgery. This was again measured post-operatively before the patient's discharge from the Post-anesthesia Care Unit.</description>
        <time_frame>Baseline, Post anesthesia care unit (PACU) - within 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 5 mL</title>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 10 mL</title>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 20 mL</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Diaphragmatic Displacement From Baseline to Post-surgery</title>
          <description>Diaphragm displacement from exhale to inhale. The baseline diaphragm measurement was obtained pre-operatively before the block was administered prior to surgery. This was again measured post-operatively before the patient's discharge from the Post-anesthesia Care Unit.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% change in diaphragm displacement ipsilateral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="43" upper_limit="88"/>
                    <measurement group_id="O2" value="60" lower_limit="21" upper_limit="98"/>
                    <measurement group_id="O3" value="65" lower_limit="45" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change in diaphragm displacement contralateral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28" lower_limit="-45" upper_limit="-10"/>
                    <measurement group_id="O2" value="-56" lower_limit="-139" upper_limit="26"/>
                    <measurement group_id="O3" value="-39" lower_limit="-114" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Considered the Analgesic Technique &quot;Helpful&quot; or &quot;Extremely Helpful&quot;</title>
        <description>Participants were asked to rate the helpfulness of their infusion:
extremely harmful
harmful
neutral
not harmful, but not helpful
helpful
extremely helpful</description>
        <time_frame>at 24 and 48 hours after discharge from the hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 5 mL</title>
            <description>Initial Bolus 0f 5 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 10 mL</title>
            <description>Initial Bolus 0f 10 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine 20 mL</title>
            <description>Initial Bolus 0f 20 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Considered the Analgesic Technique &quot;Helpful&quot; or &quot;Extremely Helpful&quot;</title>
          <description>Participants were asked to rate the helpfulness of their infusion:
extremely harmful
harmful
neutral
not harmful, but not helpful
helpful
extremely helpful</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of participants at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Outcome - Simple Shoulder Test (SST)</title>
        <description>At baseline and again at 12 weeks subjects completed the Simple Shoulder Test. This test is a series of 12 (yes/no) questions. Participants get 1 point if they answer yes (they can perform the task) and 0 if they answer no. Total possible range is from 0-12. This has been shown to be a valid, reliable and consistent for subjects up to and including 60 years of age when similar injuries (rotator cuff dysfunction) are assessed.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All study participants who received Interscalene block (ISB) using 5-20 mL of local anesthetic.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Outcome - Simple Shoulder Test (SST)</title>
          <description>At baseline and again at 12 weeks subjects completed the Simple Shoulder Test. This test is a series of 12 (yes/no) questions. Participants get 1 point if they answer yes (they can perform the task) and 0 if they answer no. Total possible range is from 0-12. This has been shown to be a valid, reliable and consistent for subjects up to and including 60 years of age when similar injuries (rotator cuff dysfunction) are assessed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SST at Baseline (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.1" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SST at 12 weeks (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="7.3" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine 5 mL</title>
          <description>Initial Bolus 0f 5 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaine 10 mL</title>
          <description>Initial Bolus 0f 10 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
        <group group_id="E3">
          <title>Ropivacaine 20 mL</title>
          <description>Initial Bolus 0f 20 ml Ropivacaine 0.75% administered as interscalene peripheral nerve block prior to surgical procedure performed with ultrasound guidance followed by a continuous infusion of Ropivacaine 0.2% using the Stryker Pain Pump II with the following setting: 3 ml bolus/demand, 4ml/hr continuous infusion with a 20 min lock-out.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig T. Hartrick, MD</name_or_title>
      <organization>William Beaumont Hospital</organization>
      <phone>248-964-3440</phone>
      <email>chartrick@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

